Cardiac Dimensions Raises $53 Million in Oversubscribed Series E Financing to Advance Carillon Mitral Contour System

Mar 21, 2025 12:50 CST Updated 12:50

Cardiac Dimensions

Developer of Novel Interventional Tools for Mitral Regurgitation

Call for Partners: 2025 Global Surgical Robotics Conference

Registration: First Global Ophthalmology Conference | Tentative Agenda Limited Seats

Registration: First Global Cardiovascular Conference | Award Application

Registration: First Global Orthopedics Conference | Award Selection

Recently, Cardiac Dimensions announced the completion of$53 million(ContractRMB 383 million) ofOversubscribed Series E Financing,Ally Bridge Group (Huiqiao Capital)Led by [Investor Name], with new investor Claret Capital Partners participating, existing investors also provided significant support.

The company designed the Carillon system, which aims to restore natural mitral valve function without damaging the mitral valve leaflets.The company plans to use the funds to complete the pivotal study of the Carillon system in the United States and support the commercialization of the system.

# Carillon Mitral Contour System

R&D Background

Pathological Mechanism of FMR:Left ventricular dilation in heart failure patients leads to incomplete closure of the anterior and posterior leaflets of the mitral valve, causing blood to regurgitate or leak through the mitral valve. This reduces the amount of oxygen-rich blood delivered by the heart to other parts of the body, impairing cardiac function and exacerbating heart failure. Data shows that up to 74% of heart failure patients suffer from FMR, which is an urgent clinical issue to address.

Current Treatment Status:Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER) was approved by the FDA for the clinical treatment of primary MR in 2013 and for FMR in 2019, becoming the focus of FMR treatment.

Cardiac Dimensions, Inc. is dedicated to developing novel interventional tools for the treatment of heart failure (HF) and functional mitral regurgitation (FMR). The company has developedCarillon SystemIs aMinimally Invasive Treatment System, Pioneering the reshaping of the mitral valve and improving FMR symptoms.

Product Information

The Carillon Mitral Contour System is the only indirect, non-contact mitral valve repair solution that can treat patients with mitral regurgitation grades of 2+, 3+, and 4+, producing annuloplasty effects while initiating left ventricular remodeling and improving...The long-term survival rate of patients.

The Carillon system consists of an implant and a delivery system. The implant adopts a shape similar to the coronary sinus, with a ribbon connecting the proximal anchor and the distal anchor. This shaping ribbon uses the heart's venous anatomy to secure the mitral valve apparatus. The implant can be delivered to the fixed position via the right heart approach through the delivery system.

Implantation Method:Implanted via percutaneous catheter procedure through a small incision in the neck into the jugular vein, the device is delivered to the optimal position in the coronary sinus without the need for general anesthesia.

Product Advantages

Short Path: Access via the right heart system from the jugular vein, with a shorter path and an implantation time of approximately 1 hour.
Easy to Operate: The percutaneous catheter implantation technique is simple, easy to perform, and has a short learning curve.
Does Not Affect Subsequent Surgery: As an indirect, non-contact mitral valve repair device, it does not affect subsequent heart failure surgical procedures and can be removed if necessary.

Regulation and Commercialization

Carillon Mitral Contour System received Australian Therapeutic Goods Administration (TGA) approval in 2020 and obtained EU MDR certification on April 26, 2023. Market operations have expanded to Australia and Europe, including Kirkland, Washington, Sydney, Australia, and Frankfurt, Germany. Some European countries have provided medical insurance reimbursement, while the United States remains in the research stage. Globally, more than 1,500 patients have been treated with the Carillon system.

# Research Data

In 2024, Cardiac Dimensions announced the research data related to the Carillon Mitral Contour System.CINCH-FMR Registry Study is a multicenter, real-world study,A total of 228 patients were followed up for up to 5 years.The interim analysis of the visit included the following content:

Safety Data - Device-Related Safety Events
Clinical efficacy — Mortality, heart failure hospitalization rate, NYHA class changes, and quality of life changes
Mechanistic Efficacy – Changes in Mitral Regurgitation (MR) and Left Ventricular (LV) Function Measured by Echocardiography

Safety results showed that the incidence of serious adverse events (SAE) within 30 days was 18.4% (42 cases) among 228 participants, and the SAE incidence within 12 months (including the 30-day period) was 46.9% (101 cases).

Among these SAEs, the incidence of device-related serious adverse events was 0.9% (2 cases) within 30 days and 1.3% (3 cases) within 12 months.

The incidence of serious adverse events related to the surgery was 2.2% (5 cases) within 30 days and 2.6% (6 cases) within 12 months.

Data shows that after treatment with the Carillon Mitral Contour System,Most patients' MR grading and NYHA classification continued to improve over five years. Of these, 58.4% of patients had trace/MR1+ regurgitation, and 57.1% of patients showed improvement in NYHA classification.

In chronic heart failure patients treated with the Carillon device, the 5-year survival rate reached 56.2%, meaning that more than half of the patients survived at least 5 years after receiving Carillon treatment—a positive treatment outcome for chronic heart failure patients.

# AboutCardiac Dimensions

Cardiac Dimensions, Inc., headquartered in Kirkland, Washington, USA, develops novel interventional tools for treating heart failure and conditions related to mitral regurgitation. The company's lead product is Carillon.^®Mitral ContourSystem^®Is a pioneering non-surgical device developed for the treatment of functional mitral regurgitation. Their system uses a catheter-based approach to remodel the mitral valve and reduce mitral regurgitation.

According to Crunchbase data,The company has previously completed 10 rounds of financing, with total funding exceeding 200 million US dollars: